Stock Events

Stock Events

Halozyme Therapeutics 

$108.17
149
+$2.05+1.93% Friday 20:00
+$0.51+0.47%Friday 23:42After hours

Statistics

Day High
108.22
Day Low
108.13
52W High
108.46
52W Low
61.23
Volume
34,541
Avg. Volume
-
Mkt Cap
12.28B
P/E Ratio
26.74
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.24
0.6
1.44
2.28
Expected EPS
2.242857
Actual EPS
N/A

Financials

22.69%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.4BRevenue
316.89MNet Income

Analyst Ratings

100.20Average Price Target
The highest estimate is 115.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HALO. It's not an investment recommendation.
NVIDIA
37
NVDA
Microsoft
32
MSFT
Alphabet
30
GOOGL
Amazon
28
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals competes in the biotech space, focusing on innovative biologic medicines, overlapping with Halozyme's therapeutic areas.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biopharmaceutical company that develops and produces medicines, including treatments in areas that Halozyme targets, making them direct competitors.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, competing with Halozyme in the biotech innovation space.
Biogen
BIIB
Mkt Cap31B
Biogen competes with Halozyme in the development of therapies for neurological and neurodegenerative diseases, among other areas.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is a research-based biopharmaceutical company that develops drugs in areas that overlap with Halozyme's therapeutic targets.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie operates in similar therapeutic areas as Halozyme, including immunology and oncology, making them competitors in the biopharmaceutical field.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals in competitive areas with Halozyme, including cancer treatments.
Pfizer
PFE
Mkt Cap152.69B
Pfizer is a global biopharmaceutical company with a wide range of products that compete across several of Halozyme's key therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb is a global biopharmaceutical company focusing on discovering, developing, and delivering innovative medicines that compete with Halozyme's portfolio.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca is a global, science-led biopharmaceutical business that operates in similar therapeutic areas as Halozyme, including oncology and immunotherapy.

About

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Show more...
CEO
Helen I. Torley
Employees
423
Country
United States
ISIN
US40637H1095
WKN
000A0DLHS

Listings

F
DE
RV7.F
MI
IT
1HALO.MI
XETRA
DE
RV7.XETRA
STU
DE
RV7.STU

0 Comments

Share your thoughts

FAQ

What is Halozyme Therapeutics stock price today?▼
The current price of HALO is $108.17 USD — it has increased by +1.93% in the past 24 hours. Watch Halozyme Therapeutics stock price performance more closely on the chart.
What is Halozyme Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Halozyme Therapeutics stocks are traded under the ticker HALO.
Is Halozyme Therapeutics stock price growing?▼
HALO stock has risen by +9.64% compared to the previous week, the month change is a +33.81% rise, over the last year Halozyme Therapeutics has showed a +50.61% increase.
What is Halozyme Therapeutics market cap?▼
Today Halozyme Therapeutics has the market capitalization of 12.28B
When is the next Halozyme Therapeutics earnings date?▼
Halozyme Therapeutics is going to release the next earnings report on November 09, 2026.
What were Halozyme Therapeutics earnings last quarter?▼
HALO earnings for the last quarter are 2.28 USD per share, whereas the estimation was 1.79 USD resulting in a +27.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Halozyme Therapeutics revenue for the last year?▼
Halozyme Therapeutics revenue for the last year amounts to 1.4B USD.
What is Halozyme Therapeutics net income for the last year?▼
HALO net income for the last year is 316.89M USD.
How many employees does Halozyme Therapeutics have?▼
As of August 23, 2026, the company has 423 employees.
In which sector is Halozyme Therapeutics located?▼
Halozyme Therapeutics operates in the Health & Wellness sector.
When did Halozyme Therapeutics complete a stock split?▼
Halozyme Therapeutics has not had any recent stock splits.
Where is Halozyme Therapeutics headquartered?▼
Halozyme Therapeutics is headquartered in SAN DIEGO, United States.